Skip to main content
. 2020 Jun 9;23(6):e25501. doi: 10.1002/jia2.25501

Figure 1.

Figure 1

A, Drug susceptibility in DBS group (n = 50 patients). B, Drug susceptibility in plasma group (n = 494 patients). Proportion of patients with resistance to antiretroviral compounds according to the Stanford HIV drug resistance database. 3TC/FTC, lamivudine/emtricitabine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; D4T, stavudine; DBS, Dried‐Blood Spot; DRV, darunavir; EFV, efavirenz; ETR, etravirine; LPV, lopinavir; NVP, nevirapine; r, ritonavir; RPV, rilpivirine; SQV, saquinavir; TDF, tenofovir disoproxil fumarate.